Drugs Made In America Acquisition II closed at $10.22 on Nov 4, up 0.10% — matching its highest close since Dec 3. Volume of 34.3K shares was 0.14× its 20-day average (below normal).
Split-adjusted performance: +0.3% over one month, +2.1% over six months.
Short interest was 111.2K shares at the Oct 15 settlement, down 8.5% from the prior report (0.2% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 155 companies (100 = best)
Industry medians: 6-month return +1.8%, revenue growth −4.4%, net margin −34.2%, P/E 41.3×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DMIIDrugs Made In America Acquisition II | $10.22 | +0.10% | +2.1% | — | — | — | $651.0M | |
| EVACEQV Ventures Acquisition Corp. II | $10.37 | 0.00% | +2.3% | — | — | — | $606.1M | Compare |
| BCSSBain Capital GSS Investment | $10.22 | +0.05% | +0.7% | — | — | — | $596.8M | Compare |
| CEPFCantor Equity Partners IV | $10.33 | −0.05% | +0.5% | — | — | — | $590.4M | Compare |
| CXIIChurchill Capital Corp XII | $10.40 | +0.48% | — | — | — | — | $577.7M | Compare |
| AEXAAmerican Exceptionalism Acquisition Corp. A | $10.74 | −0.09% | −5.5% | — | — | — | $531.2M | Compare |
| NWAXNew America Acquisition I | $10.04 | 0.00% | −0.3% | — | — | — | $500.0M | Compare |
| AACAres Acquisition Corporation III | $9.92 | −0.30% | — | — | — | — | $490.2M | Compare |
| KRSPRice Acquisition Corporation 3 | $10.47 | +0.14% | +0.7% | — | — | — | $481.4M | Compare |
No recent articles focused on Drugs Made In America Acquisition II.
Drugs Made In America Acquisition II Corp is a blank check Company.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology